New targets and therapeutic approaches for endocrine malignancies
In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in ear...
Gespeichert in:
| Veröffentlicht in: | Pharmacology & therapeutics (Oxford) Jg. 123; H. 1; S. 117 - 141 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
01.07.2009
|
| Schlagworte: | |
| ISSN: | 0163-7258, 1879-016X, 1879-016X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade. |
|---|---|
| AbstractList | In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade. In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade.In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by 131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade. In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment of choice, in case of differentiated thyroid carcinomas followed by [super]131-I-radioiodine administration. This approach is often successful in early disease; however, treatment options for advanced endocrine malignancies remain unsatisfactory and prognosis is poor. In particular, cytotoxic chemotherapy and radiation therapy often show only limited and transient efficacy and are associated with significant toxicity. Thus, new treatment options are urgently needed. Advances in the understanding of the molecular pathology of endocrine malignancies has recently led to identification of key events in endocrine oncogenesis (e.g. oncogenic RET mutations in medullary thyroid carcinoma or RET/PTC rearrangements in papillary thyroid carcinoma). These new insights are increasingly matched by new compounds (e.g. tyrosine kinase inhibitors) targeting signaling pathways essential for tumor cell survival, proliferation and metastases. Accordingly, a rapidly growing number of preclinical investigations and early clinical trials in endocrine malignancies have been initiated. First results of "targeted therapies" in medullary and differentiated thyroid carcinoma are impressive: phase II trials targeting RET or VEGF receptor kinases led to objective tumor response in up to 50% of patients. This review covers these recent molecular and clinical advances which most likely will dramatically alter the treatment of endocrine malignancies within the coming decade. |
| Author | Allolio, Bruno Weismann, Dirk Kreissl, Michael C. Fassnacht, Martin |
| Author_xml | – sequence: 1 givenname: Martin surname: Fassnacht fullname: Fassnacht, Martin – sequence: 2 givenname: Michael C. surname: Kreissl fullname: Kreissl, Michael C. – sequence: 3 givenname: Dirk surname: Weismann fullname: Weismann, Dirk – sequence: 4 givenname: Bruno surname: Allolio fullname: Allolio, Bruno |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19374919$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUFr3DAQhUVISHbT_oXiU292R5ZWli6FEJqkENpLA7mJsTzOarFlV9JS8u_rzaYEesnpXb73GOZbs9MwBWKs4FBx4OrLrpq3GMe8pYhVDWAqEBVwccJWXDemXJjHU7ZaQpRNvdEXbJ3SDgCkhPqcXXAjGmm4WbGrH_SnyBifKKcCQ1e8bM60z94VOM9xQrelVPRTLCh0k4s-UDHi4J8CBucpfWBnPQ6JPr7mJXu4-fbr-q68_3n7_frqvnSSQy5RgeOojO67tu4aA0Cd63qpW0mq55sNgiPUpm9g0zZ9TQ6FbrUxolNOKi4u2efj7nLT7z2lbEefHA0DBpr2yapG8AYkvAvWoGqtjFzAT6_gvh2ps3P0I8Zn--87C6CPgItTSpH6NwTsQYTd2TcR9iDCgrCLiKX69b-q8xmzn0KO6If3B_4C6OaVQg |
| CitedBy_id | crossref_primary_10_1007_s00423_011_0850_3 crossref_primary_10_1097_CAD_0b013e32834319c7 crossref_primary_10_1016_j_eururo_2011_07_062 crossref_primary_10_3892_ol_00000158 crossref_primary_10_1158_1541_7786_MCR_10_0162 crossref_primary_10_1634_theoncologist_2013_0458 crossref_primary_10_1210_jc_2013_3369 crossref_primary_10_1016_j_biopha_2018_11_057 crossref_primary_10_1002_hed_21376 crossref_primary_10_4081_rt_2011_e45 crossref_primary_10_1038_nrendo_2010_235 crossref_primary_10_1111_j_1365_2265_2011_04214_x crossref_primary_10_1155_2012_437569 crossref_primary_10_1007_s00441_010_0960_1 crossref_primary_10_1586_eem_09_33 crossref_primary_10_1093_qjmed_hct218 crossref_primary_10_3892_mmr_2012_1166 crossref_primary_10_1097_RLU_0000000000001760 crossref_primary_10_1210_jc_2009_2830 crossref_primary_10_3390_cancers13112775 crossref_primary_10_3892_or_2012_1988 crossref_primary_10_1089_thy_2010_0056 crossref_primary_10_1016_j_ymeth_2011_10_006 crossref_primary_10_1038_modpathol_2010_153 crossref_primary_10_1053_j_semnuclmed_2009_11_004 crossref_primary_10_1080_08941939_2021_1968981 crossref_primary_10_1155_2012_408131 crossref_primary_10_1016_j_beem_2010_10_002 crossref_primary_10_1200_JCO_2009_25_0068 crossref_primary_10_1517_14656566_2013_796931 crossref_primary_10_3892_br_2014_375 crossref_primary_10_1016_j_athoracsur_2011_07_088 crossref_primary_10_1016_j_mce_2013_07_033 crossref_primary_10_1007_s00761_012_2390_z crossref_primary_10_1530_EJE_14_0916 crossref_primary_10_1210_jc_2011_2765 crossref_primary_10_1053_j_seminoncol_2010_10_020 crossref_primary_10_3892_mmr_2017_6338 crossref_primary_10_1016_j_amjsurg_2010_04_012 crossref_primary_10_1007_s12022_012_9199_6 crossref_primary_10_1016_j_mce_2012_12_011 crossref_primary_10_1016_j_bmc_2013_01_029 crossref_primary_10_1530_EJE_14_0273 crossref_primary_10_2967_jnumed_115_160366 crossref_primary_10_1089_thy_2012_0359 crossref_primary_10_1053_j_seminoncol_2010_10_017 crossref_primary_10_1186_s13019_020_01113_2 crossref_primary_10_1556_oh_2010_28931 crossref_primary_10_1007_s40291_017_0303_y crossref_primary_10_1155_2012_234726 crossref_primary_10_1016_j_bcp_2015_10_012 crossref_primary_10_1007_s00423_011_0880_x crossref_primary_10_1111_j_1365_2265_2012_04354_x crossref_primary_10_3390_ijms23063107 crossref_primary_10_1016_j_mam_2010_02_006 crossref_primary_10_2165_11594890_000000000_00000 crossref_primary_10_1634_theoncologist_2010_0270 crossref_primary_10_1111_j_1476_5829_2012_00348_x crossref_primary_10_1056_NEJMoa1200966 crossref_primary_10_3390_ijms18061292 crossref_primary_10_1007_s00761_012_2391_y crossref_primary_10_1586_era_12_96 crossref_primary_10_1016_j_matbio_2024_10_001 crossref_primary_10_1007_s12022_010_9116_9 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7U7 C1K 7X8 |
| DOI | 10.1016/j.pharmthera.2009.03.013 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Toxicology Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1879-016X |
| EndPage | 141 |
| ExternalDocumentID | 19374919 10_1016_j_pharmthera_2009_03_013 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | --- --K --M .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29O 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9DU 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO AAYXX ABFNM ABMAC ABWVN ABXDB ABZDS ACDAQ ACGFO ACIUM ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AFFNX AFJKZ AFPUW AFTJW AFXIZ AGHFR AGQPQ AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AKBMS AKRWK AKYEP ALCLG ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CITATION CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W K-O KOM L7B M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SCC SDF SDG SDP SES SEW SPCBC SPT SSP SSZ T5K TEORI WUQ Y6R ZGI ZXP ~G- ~HD AGCQF AGRNS BNPGV CGR CUY CVF ECM EIF NPM RIG SSH 7U7 C1K 7X8 |
| ID | FETCH-LOGICAL-c410t-a60c1a698fdb2d7900edcdf48b4e6f155a0cea89f705b7f2eca38b8993d6c4613 |
| ISICitedReferencesCount | 87 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000266966500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0163-7258 1879-016X |
| IngestDate | Thu Oct 02 10:41:59 EDT 2025 Tue Oct 07 09:21:27 EDT 2025 Mon Jul 21 05:18:33 EDT 2025 Sat Nov 29 04:49:49 EST 2025 Tue Nov 18 22:33:25 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | https://www.elsevier.com/tdm/userlicense/1.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c410t-a60c1a698fdb2d7900edcdf48b4e6f155a0cea89f705b7f2eca38b8993d6c4613 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 ObjectType-Review-3 |
| PMID | 19374919 |
| PQID | 20628694 |
| PQPubID | 23462 |
| PageCount | 25 |
| ParticipantIDs | proquest_miscellaneous_67317040 proquest_miscellaneous_20628694 pubmed_primary_19374919 crossref_primary_10_1016_j_pharmthera_2009_03_013 crossref_citationtrail_10_1016_j_pharmthera_2009_03_013 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-07-00 2009-Jul 20090701 |
| PublicationDateYYYYMMDD | 2009-07-01 |
| PublicationDate_xml | – month: 07 year: 2009 text: 2009-07-00 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Pharmacology & therapeutics (Oxford) |
| PublicationTitleAlternate | Pharmacol Ther |
| PublicationYear | 2009 |
| SSID | ssj0004402 |
| Score | 2.2666996 |
| SecondaryResourceType | review_article |
| Snippet | In endocrine malignancies (thyroid carcinoma, parathyroid carcinoma, adrenocortical carcinoma, malignant pheochromocytoma) surgery is currently the treatment... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database Enrichment Source |
| StartPage | 117 |
| SubjectTerms | Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Carcinoma Clinical Trials as Topic Drug Design Endocrine Gland Neoplasms - drug therapy Endocrine Gland Neoplasms - metabolism Endocrine Gland Neoplasms - pathology Humans Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use |
| Title | New targets and therapeutic approaches for endocrine malignancies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19374919 https://www.proquest.com/docview/20628694 https://www.proquest.com/docview/67317040 |
| Volume | 123 |
| WOSCitedRecordID | wos000266966500008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 1879-016X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004402 issn: 0163-7258 databaseCode: AIEXJ dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV07b9swECacpEOXou-6j5RDkaVRQD0skqNRJEg6BBlc1JtAkVSRQJYMywnSKX89R5GSaDQG0iGLYIiSCPL7fDpS990h9E1Eac7MB_coL0iQaMUCUeRpoCYKjKLUBclVW2yCnp-z-ZxfjEZ3nRbmpqRVxW5v-fJJoYZzALaRzv4H3P1D4QT8BtDhCLDD8VHAm4hFG9_ddOGRncKqzyCuG5vqu1K1NPK_7wtwx__YSr2N769eDJmtbWiN97R2v9YKDr39hBPwxivoolMCdam9jVFfaYC59KL1hz3a39C0cAWbwQz3-qFpWdblZe1oWNUbuxS8j2iFl4y1rIyawKy2bOFgeq3WeINj1pCGVtH5j4G3ew1XR0sz_HbILudofESsqNWDeLloMQYflSbcWebN5Npd0w7ai-iEg1ncm54dz38O0tohAMyGBT7ccZt71j5q08HZsmppvZfZS_TCLTvw1NLlFRrp6jU6cOj-PcQzD9ZDfIB93N-gKXAKO05h4BT2WIAHTmGgAu45hX1OvUW_To5nP04DV3sjkElI1oFIiQxFylmh8khRTohWUhUJyxOdFuCECiK1YLygZJLTItJSxCyHxXusUpmAj_gO7VZ1pT_A3HENTmqeUkVloqkSoRSwTI14GBehpHyMaDdhmXSJ6U19lDLrIhCvsmHWTd1UnpE4g1kfo7C_c2mTszzinq8dJhlYUvN5TFS6vm7gIiPT5sn2K1IKA4G33hi9t2AOvTrwP25t-YSeD_-Lz2h3vbrWX9AzebO-bFb7aIfO2b4j3z3dsKkj |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+targets+and+therapeutic+approaches+for+endocrine+malignancies&rft.jtitle=Pharmacology+%26+therapeutics+%28Oxford%29&rft.au=Fassnacht%2C+Martin&rft.au=Kreissl%2C+Michael+C&rft.au=Weismann%2C+Dirk&rft.au=Allolio%2C+Bruno&rft.date=2009-07-01&rft.eissn=1879-016X&rft.volume=123&rft.issue=1&rft.spage=117&rft_id=info:doi/10.1016%2Fj.pharmthera.2009.03.013&rft_id=info%3Apmid%2F19374919&rft.externalDocID=19374919 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0163-7258&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0163-7258&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0163-7258&client=summon |